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AbsTrACT
background Whether pretreatment with intravenous 
thrombolysis prior to mechanical thrombectomy 
(iVT+MTe) adds additional benefit over direct 
mechanical thrombectomy (dMTe) in patients with large 
vessel occlusions (lVO) is a matter of debate.
Methods This study-level meta-analysis was presented 
in accord with the Preferred reporting items for 
systematic reviews and Meta-analyses guidelines. 
Pooled effect sizes were calculated using the inverse 
variance heterogeneity model and displayed as summary 
Odds ratio (sOr) and corresponding 95% confidence 
interval (95% ci). sensitivity analysis was performed 
by distinguishing between studies including dMTe 
patients eligible for iVT (iVT-e) or ineligible for iVT 
(iVT-in). Primary outcome measures were functional 
independence (modified rankin scale≤2) and mortality 
at day 90, successful reperfusion, and symptomatic 
intracerebral hemorrhage.
results Twenty studies, incorporating 5279 patients, 
were included. There was no evidence that rates of 
successful reperfusion differed in dMTe and iVT+MTe 
patients (sOr 0.93, 95% ci 0.68 to 1.28). in studies 
including iVT-in dMTe patients, patients undergoing 
dMTe tended to have lower rates of functional 
independence and had higher odds for a fatal outcome 
as compared with iVT+MTe patients (sOr 0.78, 95% ci 
0.61 to 1.01 and sOr 1.45, 95% ci 1.22 to 1.73). 
however, no such treatment group effect was found 
when analyses were confined to cohorts with a lower 
risk of selection bias (including iVT-e dMTe patients).
Conclusion The quality of evidence regarding the 
relative merits of iVT+MTe versus dMTe is low. When 
considering studies with lower selection bias, the data 
suggest that dMTe may offer comparable safety and 
efficacy as compared with iVT+MTe. The conduct of 
randomized-controlled clinical trials seems justified.
InTroduCTIon
Seven randomized-controlled studies have consis-
tently shown that patients with a large vessel occlu-
sion (LVO) in the anterior circulation benefit from 
mechanical thrombectomy (MTE) following intra-
venous thrombolysis (IVT) with tPA.1–7 Currently 
it is unclear if IVT before MTE adds additional 
benefit8–11 and this question will be assessed in two 
randomized-controlled studies (SWIFT DIRECT, 
MR CLEAN NO IV). The individual patient 
data meta-analysis of the pivotal thrombectomy 
trials found no interaction between the treatment 
effect size of MTE and IVT pretreatment status12 
and a recently published study-level meta-anal-
ysis found no significant difference in outcome 
between patients with and without pretreatment 
with IVT.13 In contrast, another meta-analysis 
has suggested that IVT+MTE patients had better 
functional outcomes, lower mortality, higher rates 
of successful recanalization, and equal odds of 
symptomatic intracerebral hemorrhage compared 
with patients treated with direct MT (dMTE).14 
However, the aforementioned analyses may in part 
be confounded by the eligibility for IVT, potentially 
leading to group imbalances in stroke etiology, risk 
factors, and time to treatment.
To account for such group imbalances more 
systematically, the present meta-analysis on a 
comparison of IVT+MTE versus dMTE will distin-
guish between studies including dMTE patients 
eligible for IVT (IVT-E) and studies including 
dMTE patients ineligible for IVT (IVT-IN), as the 
latter may be a major source of selection bias. In 
addition, baseline risk factor distribution in both 
groups will be evaluated to quantify selection bias.
MeThods
This study-level meta-analysis was presented in 
a manner adherent to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines.15 The checklist outlined 
by the Meta-analysis Of Observational Studies 
in Epidemiology (MOOSE) consortium was also 
applied. The authors declare that all supporting 
data are available within the article and its online 
supplementary files. Extracted raw data can be 
found in the online supplementary dataset 1.
search strategy and selection criteria
Information about the search strategy and accessed 
databases can be found as additional information in 
the Online Supplement (supplementary additional 
information 1 and table I-IV).
All identified studies were imported into EndNote 
(version X, Clarivate Analytics, Phiadelphia, USA) 
and an automatic deduplication was performed. 
After the deduplication procedure, studies were 
reviewed for eligibility concerning the quantitative 
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analysis by two independent raters (JK, PM) and by a third rater 
in cases of discrepancies (UF). Prespecified inclusion criteria can 
be found in the Online Supplement (supplementary additional 
information 2).
Studies were categorized as comparing dMTE in IVT-eligible 
patients (=IVT-E) with IVT+MTE in IVT-eligible patients or 
comparing dMTE in IVT-ineligible patients (=IVT-IN) with 
IVT+MTE in IVT-eligible patients. Studies reporting on both 
IVT-E and IVT-IN patients were included if separate anal-
yses of these groups had been presented in the published full 
text article, or if the relevant data discriminating between the 
two groups were made available after contacting the respec-
tive corresponding authors. If a study provided comparison 
of a matched and unmatched control group, the matched-pair 
analysis was used for further calculation in order to reduce the 
risk of bias. Any matched-pair analysis was excluded from the 
analyses regarding risk-factor distribution between dMTE and 
IVT+MTE patients.
extraction of baseline and outcome data
Data were extracted by JK according to a standardized extraction 
sheet and cross-checked by a second reader. A full list with the 
study data and outcomes extracted, as well as contact processes 
with the authors can be found as additional information in the 
Online Supplement (supplementary additional information 3).
statistical analysis and quality assessment
Pooled effect sizes were calculated using the inverse variance 
heterogeneity (IVhet) model, assuming heterogeneous studies 
and the presence of multiple true effect sizes.16 The assump-
tion was based on the heterogeneous inclusion and exclusion 
criteria of the respective studies. The IVhet model is considered 
as an improved alternative to the random effect model which 
uses an estimator under the fixed effect model assumption with 
a quasi-likelihood based variance structure.16 For all outcomes 
included in the analysis, we calculated the corresponding 
summary ORs and respective 95% CIs to express the compar-
ison of dMTE vs IVT+MTE.
Pooled effect sizes were further calculated and stratified 
according to IVT-E and IVT-IN studies. Other subgroup analyses 
were performed according to the study type (ie, confined analysis 
to RCT subgroup analyses). For further information regarding 
influence analysis, assessment of heterogeneity and evaluation 
of publication bias, see Online Supplement (supplementary 
additional information 4). Quality assessment was performed 
as denoted in the Online Supplement (supplementary additional 
information 5). Data were analyzed and displayed using the soft-
ware package MetaXL (EpiGear International, Sunrise Beach, 
Queensland, Australia) for Microsoft Excel.
resulTs
literature search
The search strategies yielded 2747 unique publications, among 
which 2617 were excluded on abstract and title screening. After 
retrieving the full texts of the remaining 130 studies, 20 met 
all study selection criteria and were included into quantitative 
synthesis (see online supplementary figure 1 for literature search 
flow diagram, table 1 for study characteristics).1 5 17–33 Reporting 
rates of the primary and secondary outcomes are denoted in 
online supplementary table V. Further information regarding the 
results of the literature search is provided in the Online Supple-
ment (supplementary additional information 6).
baseline characteristics and risk factor distribution
For detailed information see Supplementary additional  infor-
mation 7. In short, IVT-IN dMTE patients were treated later 
and had more comorbidities including higher odds for a medical 
history of atrial fibrillation (sOR 1.94, 95% CI 1.50 to 2.50, 
online supplementary figure IV) and prior cerebrovascular 
events (sOR 1.94, 95% CI 1.60 to 2.35, online supplementary 
figure IV).
Functional independence at day 90
Rates of functional independence at 3 months were reported 
in 17 studies (2 IVT-E, 1 IVT-E, and IVT-IN, 14 IVT-IN, 4657 
patients). Overall, there was a non-significant trend that patients 
undergoing dMTE have lower rates of functional independence 
at day 90 as compared with IVT+MTE patients (sOR 0.82, 
95% CI: 0.65 to 1.03, figure 1). However, heterogeneity was 
substantial (I²: 51%, Q=35.01, P=0.01). Influence analysis 
provided evidence that the exclusion of three single studies 
(Weber et al,19 Abilleira et al,21 and Sanak et al31) would result 
in a significant association between dMTE and lower rates of 
good functional outcome (data not shown). Analysis confined 
to RCTs, comparing dMTE in IVT-IN patients and IVT+MTE 
in IVT-E patients, showed no differences between the groups, as 
evidenced by a point estimation of sOR 0.80 (95% CI 0.58 to 
1.12, online supplementary figure VII).
Among just the studies comparing dMTE in IVT-E patients 
with IVT+MTE in IVT-E patients, rates of functional indepen-
dence at 3 months did not differ between the treatment groups 
(sOR 1.08, 95% CI 0.67 to 1.76, figure 1).
Mortality at day 90
Rates of mortality at day 90 were reported in 18 studies (2 
IVT-E, 1 IVT-E/IN, and 15 IVT-IN studies, 4929 patients). 
Patients undergoing dMTE had higher odds for a fatal outcome 
at day 90 (sOR 1.35, 95% CI 1.07 to 1.71, figure 2). No substan-
tial heterogeneity was noted, with 39%, 27.70, and P=0.05 
for I2, Q, and corresponding p, respectively. Influence analysis 
provided evidence that the exclusion of one study (Minnerup 
et al26) resulted in loss of significance (data not shown). Restric-
tion to RCT data, comparing dMTE in IVT-IN patients and 
IVT+MTE in IVT-E patients, provided a comparable point esti-
mate as other IVT-IN studies (sOR 1.83, 95% CI 1.16 to 2.91, 
online supplementary figure VIII).
In the analysis confined to studies comparing dMTE in IVT-E 
patients with IVT+MTE in IVT-E patients, no effect of treat-
ment group on mortality was noted (sOR 0.84, 95% CI 0.40 to 
1.75, figure 2).
successful reperfusion
Nineteen studies reported on rates of successful reperfusion of 
IVT+MTE versus dMTE (2 IVT-E, 1 IVT-E, and IVT-IN, 16 
IVT-IN, 4220 patients). Overall, there was no evidence that 
rates of successful reperfusion differed in dMTE and IVT+MTE 
patients (sOR 0.93, 95% CI 0.68 to 1.28, figure 3). I² and 
Cochrances Q statistics were I²=51% (95% CI: 19% to 71%) 
and Q=39.02, P<0.01, indicating substantial heterogeneity. 
Influence analysis did not provide evidence that the sOR changed 
significantly when excluding single studies (data not shown). 
Similar rates of successful reperfusion were also observed when 
the analysis was confined to analyses of RCTs with dMTE in 
IVT-IN patients and IVT+MTE in IVT-E patients (sOR 1.32, 
95% CI 0.89 to 1.95, online supplementary figure IX). Among 
nine studies (1753 patients) reporting rates of complete (TICI3) 
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reperfusion, no difference between dMTE and IVT+MTE 
patients was noted (sOR 0.98, 95% CI 0.80 to 1.21, see online 
supplementary figure X).
When assessing the rates of successful reperfusion only for 
studies comparing dMTE in IVT-E patients with IVT+MTE in 
IVT-E patients (n=531 patients), there was a non-significant 
trend for higher rates of successful reperfusion in the dMTE 
group (sOR 1.67, 95% CI 0.95 to 2.94, figure 3).
symptomatic intracerebral hemorrhage
Rates of sICH were reported in 16 studies (3903 patients, 
see table 1 for respective definition of sICH in the different 
studies). IVT+MTE patients nominally had more sICH (sOR 
0.86, 95% CI 0.63 to 1.17, figure 4) without reaching statistical 
significance.
Considering only the studies comparing dMTE in IVT-E 
patients with IVT+MTE in IVT-E patients, no treatment group 
effect on sICH rates was noted (sOR 0.95, 95% CI 0.51 to 1.76, 
figure 4).
Asymptomatic intracerebral hemorrhage
The reporting frequency for aICH was 75% (15/20 studies, 3635 
patients). Two IVT-E, 12 IVT-IN studies and one IVT-E/IN study 
had analyzable data. The odds for aICH did not differ between 
dMTE and IVT+MTE patients (sOR 0.93, 95% CI 0.72 to 1.19, 
online supplementary figure XI). The observed heterogeneity 
was low overall.
However, in the analysis restricted to studies comparing dMTE 
in IVT-E patients with IVT+MTE in IVT-E patients, dMTE was 
associated with lower rates of aICH (sOR 0.49, 95% CI 0.30 to 
0.81, online supplementary figure XI).
Quality and bias assessment
Risk of bias was noted in all studies, with the most common 
source being nonrandom allocation to treatment groups, present 
in all. Studies differed in sources of potential bias most often with 
regard to: blinding of outcome assessment; comparability of base-
line characteristics between treatment groups; and non-reporting 
of whether some patients not undergoing MTE after IVT did so 
because of preinterventional reperfusion or because of neurolog-
ical improvement or other reasons (intention to treat reporting, 
see online supplementary table VII). A minor to moderate funnel 
and doi plot asymmetry was present for most of the analyses 
performed (see online supplementary figure XII).
dIsCussIon
A substantial body of observational and indirect RCT compar-
ison investigations analyzing direct mechanical thrombectomy 
Figure 1 Summary OR of dMTE patients for day 90 mRS ≤2. *matched-pair analysis; IVT-E, IVT-eligible dMTE patients; IVT-IN, IVT-ineligible dMTE 
patients.
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alone vs combined intravenous tPA plus mechanical thrombec-
tomy has now been accumulated, comprising 20 studies and 
5279 patients. Intriguingly, in the pooled analysis of three of the 
studies contrasting both treatment strategies in highly compa-
rable patients  – those eligible for IV tPA – direct mechanical 
thrombectomy alone showed equal rates of substantial reperfu-
sion and lower rates of asymptomatic hemorrhagic transforma-
tion, though no differences in 3-month functional independence 
and mortality. Treatment strategy effects were less consistent 
when these data were combined with studies contrasting both 
treatment strategies in less comparable patients (patients with 
dMTE who were ineligible for IVT). In these patients, dMTE 
compared with IVT+MTE was associated with a tendency for 
less symptomatic hemorrhage but higher 3-month mortality.
Comparison with previous meta-analyses
The findings of the present systematic analysis are consonant 
by definition with prior component studies, as the meta-anal-
ysis encompasses all identified individual investigations. Our 
findings do however contrast with those of a recent meta-anal-
ysis.14 That study reported lower reperfusion rates and inferior 
clinical outcomes among dMTE compared with IVT+MTE 
patients.14 However, that analysis was confined to a smaller 
group of studies (13 instead of 20), and included only one of 
the three studies with comparable, IVT-eligible patients in both 
treatment arms. In contrast, another meta-analysis performed 
by Phan et al13 showed equal rates of good functional outcome 
and 90-day mortality between dMTE and IVT+MTE patients. 
These discrepant results may partially be due to different inclu-
sion criteria, as Phan et al13 also included studies evaluating 
posterior circulation strokes and a few studies which included 
first-generation mechanical thrombectomy devices.13 34 Another 
reason which may partially explain these discrepancies is the 
difference with regards to the inclusion of studies assessing 
dMTE in IVT-eligible patients.13 14 The current, meta-analysis 
suggests that, among IVT-eligible patients, dMTE is associated 
with equal rates of good angiographic results and may protect 
from asymptomatic hemorrhagic transformation. Hence, some 
reassurance is provided that reperfusion rates are unlikely to 
be substantially lower for dMTE patients. The results suggests 
caution in reaching conclusions from comparisons of dMTE in 
IVT-ineligible patients with IVT+MTE in IVT-eligible patients. 
The features that cause patients to be IVT-ineligible also often 
predispose to lesser technical and clinical success. Those factors 
may include greater time since onset (allowing more thrombus 
impaction), recent surgery (greater co-morbidities), and anti-
coagulation therapy at onset (increased hemorrhagic risk). The 
current analysis fails to provide evidence for clear benefits of one 
treatment approach over the other but rather points toward clin-
ical equipoise regarding the best treatment strategy and wariness 
Figure 2 Summary OR of dMTE patients for fatal outcome at day 90. *matched-pair analysis; IVT-E, IVT-eligible dMTE patients; IVT-IN, IVT-ineligible 
dMTE patients.
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regarding comparison of unlike patients, indicating a need for 
formal testing in randomized-controlled trials.
reperfusion
Numerous theoretical considerations have been proposed 
supporting both potentiation of MTE reperfusion by preceding 
IVT (eg, thrombus softening and lysis of downstream emboli),35 
and reduction of MTE reperfusion by preceding IVT (eg, 
thrombus fragmentation and procedure delay with further clot 
organization).36 We analyzed rates of complete (TICI 3) as well 
as successful (TICI 2B/3) reperfusion, as multiple studies have 
suggested that complete reperfusion is associated with better 
clinical outcomes than moderately successful reperfusion.37–42 
As it is conceivable that IV fibrinolysis might distinctively clear 
small distal thrombi,35 enabling complete rather than moder-
ately successful reperfusion, this topic is of interest. However, in 
concordance with the findings regarding successful reperfusion, 
no difference was noted in rates of complete reperfusion (TICI3) 
between dMTE and IVT+MTE strategies.
Functional outcome
Important confounding factors were observed in the analysis 
comparing dMTE in IVT-ineligible patients with IVT+MTE 
in IVT-eligible patients. The IVT-ineligible patients had worse 
baseline profiles, including more frequent history of atrial fibril-
lation, more frequent history of prior cerebrovascular events, 
and longer total ischemia time prior to start of the thrombec-
tomy procedure. Patients with ischemic stroke and history of 
atrial fibrillation (AF), compared with non-AF patients, have 
larger cerebral infarcts, more severe presenting deficits, more 
frequent post-stroke medical and neurological complications, 
and worse long-term clinical outcomes.43–45 Especially when 
favorable outcome is evaluated with the modified Rankin Scale, 
stroke outcomes have been shown to be dependent on preex-
isting comorbidities such as prior strokes.46 Finally, longer time 
to treatment start is a substantial risk factor for worsened clin-
ical outcome.47 Importantly, no difference in rates of good func-
tional outcome were noted when analyses was limited to dMTE 
patients who were IVT-eligible. This observation was also shared 
in a patient-level pooled analyses of the data from two articles 
included in the IVT-eligible subgroup.11
hemorrhagic complications
Hemorrhagic transformation is a feared complication of cere-
bral ischemia associated with high morbidity and mortality.48 
In patients treated with MTE, occurrence of intracranial 
Figure 3 Summary OR of dMTE patients for successful reperfusion. *matched-pair analysis; IVT-E, IVT-eligible dMTE patients; IVT-IN, IVT-ineligible 
dMTE patients.
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hemorrhage is favored by delayed treatment, a proximal occlu-
sion site, cardioembolic origin, poor collaterals, reperfusion 
success, and extended early ischemic damage.49–52 In patients not 
treated with MTE, IV tPA facilitates the occurrence of intracra-
nial hemorrhage as compared with placebo.53 54 In the present 
meta-analysis, we found signals – albeit weak –  that IV tPA 
added to MTE, compared with MTE alone, increases the likeli-
hood of hemorrhagic transformations.
lIMITATIons
This study has several important limitations. First, all studies 
included in the meta-analysis had potential sources of bias, 
limiting the strength of conclusions. Second, heterogeneity 
between studies was noted for some analyses. The use of a 
conservative statistical approach (inverse variance heteroge-
neity model)24 and of sensitivity analyses dropping individual 
studies mitigated, but presumably could not entirely account 
for, heterogeneity effects. Third, we implemented the data of 
two studies, which performed case-matching in order to reduce 
the risk of bias owning to differences in baseline characteristics. 
However, case-matching may also increase the risk of hidden 
bias and may thus produce artificial results.25 Fourth, we did 
not publish an analysis protocol ahead of the initiation of the 
meta-analysis. Last, the most important limitation arises due to 
the fact that several of the studies did not report on patients 
who were treated with a combined IVT+MTE strategy, but only 
received the IVT component as they reperfused or clinically 
improved with IVT alone, before MTE initiation. As a result, 
this potentially important advantage of the bridging approach 
was not fully incorporated in the present analysis and deserves 
future research. Although IVT clearly favors recanalization in 
patients with LVO,55 reperfusion may not occur early enough 
and reported rates of reperfusions after IVT and prior to the 
start of MTE are low in patients with an intention to bridge 
(~10%).1 3–6 56–59 60 Especially non-transfer patients with short 
needle to groin puncture intervals, a proximal occlusion, and a 
high thrombus burden are unlikely to respond to IVT.58 59 Given 
these considerations, SWIFT DIRECT (https:// clinicaltrials. gov/ 
ct2/ show/ NCT03192332) will only include non-transfer patients 
with a proximal occlusion in whom endovascular treatment can 
be initiated rapidly. 
ConClusIon
The overall quality of evidence regarding the relative merits of 
IVT+MTE versus dMTE is low. In contrast to previous synopses 
and when analysis is confined to studies with a low risk of selec-
tion bias (ie, comparable IVT-eligible patients in both treatment 
strategy groups), the data suggest that for patients who finally 
undergo MTE, dMTE may offer comparable safety and effi-
cacy as compared with IVT+MTE. Outcome comparisons yield 
mixed results when less comparable patients are considered 
(dMTE in IVT-ineligible patents vs IVT+MTE in IVT-eligible 
Figure 4 Summary OR of dMTE patients for symptomatic intracerebral hemorrhage. *matched-pair analysis; IVT-E, IVT-eligible dMTE patients; IVT-
IN, IVT-ineligible dMTE patients.
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patients), but there is evidence of confounding by indication. 
The available data does provide substantial indications of clinical 
non-inferiority, suggesting that the conduct of randomized clin-
ical trials evaluating dMTE versus IVT+MTE in LVO patients 
is appropriate when including only major vessel occlusions and 
when rapid access to endovascular treatment can be assured. The 
value of preinterventional recanalization in IVT+MTE needs 
further evaluation and should be reported more consistently.
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